A130FABA-F55F-412D-940E-7305057B4D1A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 30.420499342969777
- age_years
- 44
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.403
- WNT_BETA_CATENIN_SIGNALING+0.379
- NOTCH_SIGNALING+0.373
- MITOTIC_SPINDLE+0.332
- DNA_REPAIR+0.291
- G2M_CHECKPOINT+0.279
- MYC_TARGETS_V2+0.278
- TGF_BETA_SIGNALING+0.271
- E2F_TARGETS+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.115
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.383
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.363
- KRAS_SIGNALING_DN-0.351
- OXIDATIVE_PHOSPHORYLATION-0.337
- COAGULATION-0.317
- MYOGENESIS-0.299
- ESTROGEN_RESPONSE_LATE-0.294
- ANGIOGENESIS-0.293
- ALLOGRAFT_REJECTION-0.284
- COMPLEMENT-0.272
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.918 |
| 2 | 9CC5EB30-A8C2-4FDF-8074-467AA98ED1CA | — | — | 0.897 |
| 3 | SRR934951 | — | — | 0.896 |
| 4 | SRR934847 | — | — | 0.892 |
| 5 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.889 |
| 6 | 7C225672-8372-4202-A749-3D8E9A0747CC | — | — | 0.887 |
| 7 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.881 |
| 8 | 0730F3DB-384B-43E6-A69F-BF3F7C2CCE78 | — | — | 0.876 |
| 9 | SRR934853 | — | — | 0.872 |
| 10 | SRR934805 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.403 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.379 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.373 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.332 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.291 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.279 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.278 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.271 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.115 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.102 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.078 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.075 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.033 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.028 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.014 | Idelalisib | — uncovered |